Skip to main content
SpringerLink
Log in

Diabetes II

  • Conference paper
90. Kongreß

Part of the book series: Verhandlungen der Deutschen Gesellschaft für Innere Medizin ((VDGINNERE,volume 90))

  • 32 Accesses

Zusammenfassung

Nur sehr wenige Autoren lehnen Sulfonylharnstoffe in der Medikation des Typ II-Diabetes generell ab [10]. Mit dem Begriff „Sekundärversagen einer Sulfonylharnstofftherapie“ wird allerdings zum Ausdruck gebracht und wohl auch allgemein akzeptiert, daß die blutzukkersenkende Wirkung von Sulfonylharnstoffen zu diesem Zeitpunkt, wo zur befriedigenden Stoffwechselkontrolle des Typ II-Diabetes exogenes Insulin notwendig wird, nicht mehr besteht. Dies sollte jedoch erneut diskutiert werden, da nach neueren Erkenntnissen neben dem zentralen Effekt der Sulfonylharnstoffe auf die B-Zelle des Pankreas [6, 11] eine zusätzliche periphere Wirkung auf Rezeptor/Postrezeptorebene [2, 7, 8] an der Zelle des Erfolgsorgans besteht. Ziel dieser Studie war es deshalb, die in Frage gestellte Wirkung der Sulfonylharnstoffe im „Sekundärversagen einer Sulfonylharnstofftherapie“ bezüglich dieser unterschiedlichen Aspekte zu untersuchen.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 69.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 74.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Bachmann W, Sieger C, Lacher F, Lotz N (1981) Binding of biosynthetic human insulin to erythrocytes of normal and insulin-dependent diabetic subjects: Comparison with pork and human pancreatic insulin. Diabetes Care 4: 215–219

    Article  PubMed  CAS  Google Scholar 

  2. Beck-Nielsen H, Pederson O, Lindskov HO (1979) Increase insulin sensitivity and cellular insulin binding in obese diabetics following treatment with glibenclamide. Acta Endocrinol (Kbh) 90: 451–462

    CAS  Google Scholar 

  3. Flückiger R, Winterhalter KH (1978) In vitro synthesis of hemoglobin Al c. FEBS Lett 71: 356–360

    Article  Google Scholar 

  4. Gerbitz KG, Kemmler W (1978) Method for rapid quantitation and characterization of insulin antibodies. Clin Chem 24: 890–984

    PubMed  CAS  Google Scholar 

  5. Heding LG (1975) Radioimmunological determination of human C peptide in serum. Diabetologia 11: 541–548

    Article  PubMed  CAS  Google Scholar 

  6. Joost HG, Hasselblatt A (1979) Insulin release by tolbutamide and glibenclamide. Naunyn-Schmiedebergs Arch Pharmacol 306: 185–188

    Article  PubMed  CAS  Google Scholar 

  7. Olefsky JM, Reaven GM (1976) Effect of sulfonylurea therapy on insulin binding to mononuclear leukocytes of diabetic patients. Am J Med. 60: 89–95

    Article  PubMed  CAS  Google Scholar 

  8. Reaven G, Dray J (1967) Effect of chlorpropamide on serum glucose and immunoreactive insulin concentrations in patients with maturity-onset diabetes mellitus. Diabetes 16: 487–492

    PubMed  CAS  Google Scholar 

  9. Sartor G, Melander A, Scherstén B, Wählin-Boll E (1980) Serum glibenclamide in diabetic patients and influence of food on the kinetics and effects of glibenclamide. Diabetologia 18: 17–22

    Article  PubMed  CAS  Google Scholar 

  10. Shiao-Wei Shen, Bressler R (1977) Clinical pharmacology of oral antidiabetic agents (second of two parts). N Engl J Med 296: 787–793

    Article  PubMed  CAS  Google Scholar 

  11. Taljedal IB (1974) Uptake of glibornuride by microdissected pancreatic islets. Horm Res 5:211–216

    Article  PubMed  CAS  Google Scholar 

  12. Bachmann W, Sieger C, Haslbeck M, Lotz N (1981) Combination of insulin and glibenclamide in the treatment of adult-onset diabetes (tape 2). Diabetologia 21: 245

    Google Scholar 

  13. Beck-Nielsen H (1978) The pathogenetic role of an insulin receptor defect in diabetes mellitus of obese. Diabetes 27: 1175

    Article  PubMed  CAS  Google Scholar 

  14. Beck-Nielsen H, Pedersen O, Linkskov HO (1979) Increased insulin sensitivity and cellular insulin binding in obese diabetics following treatment with glibenclamide. Acta Endocrinol (Kbh) 90: 451

    CAS  Google Scholar 

  15. DeFronzo R, Siebert D, Hendler R (1978) Direct evidence of insulin resistance in maturity onset diabetes. Diabetes 27: 431

    Google Scholar 

  16. Bachmann W (1982) Insulin plus Sulfonylharnstoff — eine mögliche Kombination? Dtsch Med Wochenschr 107: 1963

    Article  Google Scholar 

  17. Fabrykant M, Sahe BI (1959) Combined insulin-tolbutamide therapy in the management of insulin-dependent diabetes. Ann NY Acad Sci 82: 585

    Article  PubMed  CAS  Google Scholar 

  18. Fonseca VA (1981) Sulphonylurea and insulin combination in the treatment of diabetes. Br Med J 283:797

    Article  CAS  Google Scholar 

  19. Hamelbeck H, Klein W, Zoltobrocki M, Schöffling K (1982) Glibenclamid-Insulin-Kombinationsbehandlung bei Sekundärversagen der Sulfonylharnstoff-Therapie. Dtsch Med Wochenschr 107: 1581

    Article  PubMed  CAS  Google Scholar 

  20. Marschall M, Wiederholt R, Setiakusuma I, Henrichs HR (1981) Klinische Untersuchungen zur Sulfonylharnstoff-Insulin-Kombinationstherapie beim Diabetes nach Tablettenversagen. Aktuel Endokrinol 2: 104

    Google Scholar 

  21. Olefsky JM, Reaven M (1976) Effects of sulfonylurea therapy on insulin binding to mononuclear leukocytes of diabetic patients. Am J Med 60:89

    Article  PubMed  CAS  Google Scholar 

  22. Otto H, Mikosch M, Otto-Bendfeldt E (1966) Indikationen für die kombinierte Anwendung von Insulin und Sulfonylharnstoffen in der Diabetesbehandlung. Med Welt 17: 1864

    Google Scholar 

  23. Stratmann FW (1970) Die kombinierte Behandlung des Diabetes mit Insulin und Sulfonylharnstoffen. In: Behringer A, Deutsch E (Hrsg) Verhandlungen des I. Internationalen Donau-Symposium über Diabetes mellitus. Verlag Wiener Medizinische Akademie

    Google Scholar 

  24. Traumann KJ, Hosl W, Grom E, Wittemann G (1982) Kombination von Insulin und Sulfonylharnstoffen bei der Therapie des Diabetes mellitus vom Erwachsenen-Typ. Dtsch Med Wochenschr 107: 180

    Article  PubMed  CAS  Google Scholar 

  25. Volk BW, Lazarus SS (1959) Significance of effectiveness of combined insulin orinase treatment in maturity-onset-diabetes. Am J Med Sci 237: 1

    Article  PubMed  CAS  Google Scholar 

  26. Subbiah MT (1978) Prostaglandins and the arterial wall: An avenue for research in the pathogenesis of atherosclerosis. Mayo Clin Proc 53: 60

    PubMed  CAS  Google Scholar 

  27. Moncada S, Vane JR (1979) Arachidonate acid metabolites and the interactions between platelets and blood-vessel walls. N Engl J Med 300: 1142–1147

    Article  PubMed  CAS  Google Scholar 

  28. Halushka PV, Lurie D, Colwell JA (1977) Increased synthesis of prostaglandin-E-like material by platelets from patients with diabetes mellitus. N Engl J Med 297: 1306

    Article  PubMed  CAS  Google Scholar 

  29. Davies TME, Mitchell MD, Turner RC (1979) Prostacyclin and thromboxane metabolites in diabetes. Lancet 2: 789–790

    Article  Google Scholar 

  30. Johnson M, Harrison HE, Raftery AT, Elder JB (1979) Vascular prostacyclin may be reduced in diabetes. Lancet 1: 325–326

    Article  PubMed  CAS  Google Scholar 

  31. Canadian Cooperative Study Group (1978) A randomized trial of aspirin. N Engl J Med 229: 53

    Article  Google Scholar 

  32. Anturane Reinfarktion Trial Research Group (1978) Sulfinpyrazone in the prevention of cardiac death after myocardial infarction. N Engl J Med 298: 289

    Article  Google Scholar 

  33. Jackson CA, Preston FE, Greaves M (1981) Dipyridamole reverses the inhibitory effect of aspirin on prostacyclin synthesis. Thromb Haemostas 46:26

    Google Scholar 

  34. Demers LM, Kern D, Patrono C, Patrignani P, Preston FE (1981) Inhibition of prostacyclin and platelet thromboxane A2 by aspirin. N Engl J Med 304: 1173–1175

    Article  Google Scholar 

  35. Randall MJ, Parry MJ, Hawkeswood E, Cross PE, Dickinson RP (1981) UK 37,248–01, a novel, selective thromboxane-synthetase inhibitor with platelet anti-aggregatory and anti thrombotic activity. Thromb Res 23: 145–162

    Article  PubMed  CAS  Google Scholar 

  36. Tyler HM, Saxton CAP, Parry MJ (1981) Administration to man of UK 37,248–01, a selective inhibitor of thromboxan-synthetase. Lancet 1: 629–632

    Article  PubMed  CAS  Google Scholar 

  37. Vermylen J, Deckmyn H (1983) Reorientation of prostaglandin endoperoxide metabolism by a thromboxan-synthetase inhibitor: in vivo and clinical observation. Br J Clin Pharmacol 15: 17–22

    Article  Google Scholar 

  38. Parry MJ (1983) Effects of thromboxan-synthetase inhibition on arachidonate metabolism and platelet behaviour. Br J Clin Pharmacol 15: 23–29

    Article  CAS  Google Scholar 

  39. Bertelé V, Falanga A, Roncaglioni MC, Cerletti C, de Gaetano G (1982) Thromboxane-synthetase inhibition results in increased platelet sensitivity to prostacyclin. Thromb Haemostas 47: 294

    Google Scholar 

  40. Tyler HM (1981) Thromboxan-synthetase inhibition. Lancet 1: 1313

    Article  PubMed  CAS  Google Scholar 

  41. Cicmir I, Grüneklee D, Morguet A, Berger H, Kley HK, Lehmacher W, Gries FA (1977) Studies of heart oscillation in diabetics at rest. In: Gries FA, Freund HJ, Rabe F, Berger H (eds) Aspects of autonomic neuropathy in diabetes. Horm Metab Res (Suppl) 9:73–76

    Google Scholar 

  42. Morguet A, Springer HJ (1981) Microcomputer-based measurement of beat-to-beat intervals ans analysis of heart rate variability. Med Progr Technol 8: 77–82

    CAS  Google Scholar 

  43. Cicmir I, Kashiwagi I, Berger H, Koschinsky T, Petersohn HJ, Gries FA (1984) Reversibility of cardiac autonomic nerve dysfunctions (CAND) in type 1 diabetics. Diabetes (Suppl) (in press)

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Krankenhauses München-Schwabing und Forschergruppe Diabetes, III. Med. Abteilung, München, Deutschland

    N. Lotz, W. Bachmann, M. Haslbeck & H. Mehnert

  2. III. Medizinische Klinik und Poliklinik, Universität Gießen, Deutschland

    G. Sachse, E. Mäser & K. Federlin

  3. Zentrum der Inneren Medizin, Abtlg. für Endokrinologie, Frankfurt Main, Deutschland

    C. Rosak, P. H. Althoff, E. Schifferdecker, E. Jungmann & K. Schöffling

  4. Diabetes-Forschungsinstitut, Düsseldorf, Deutschland

    I. Cicmir, A. Petersohn, H. J. Petersohn, H. Berger, T. Koschinsky, S. Kashiwagi & F. A. Gries

Authors
  1. N. Lotz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W. Bachmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Haslbeck
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H. Mehnert
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G. Sachse
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. E. Mäser
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. K. Federlin
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. C. Rosak
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. P. H. Althoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. E. Schifferdecker
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. E. Jungmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. K. Schöffling
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. I. Cicmir
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. A. Petersohn
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. H. J. Petersohn
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. H. Berger
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. T. Koschinsky
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. S. Kashiwagi
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. F. A. Gries
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 1984 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Lotz, N. et al. (1984). Diabetes II. In: 90. Kongreß. Verhandlungen der Deutschen Gesellschaft für Innere Medizin, vol 90. J.F. Bergmann-Verlag, Munich. https://doi.org/10.1007/978-3-642-85457-6_18

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-85457-6_18

  • Publisher Name: J.F. Bergmann-Verlag, Munich

  • Print ISBN: 978-3-8070-0342-9

  • Online ISBN: 978-3-642-85457-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation